Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHX9 | Q08211 | 1/20 | 0.71 |
| ▸ | EGFR | P00533 | 12/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.61 |
| ▸ | KDR | P35968 | 12/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30543980 | 1.00 | DHX9 (0.71) | DHX9EGFRFGFR1KDRKEAP1 | |
| SCHEMBL25433507 | 0.85 | DHX9 (0.70) | DHX9EGFRFGFR1KDRKEAP1 | |
| SCHEMBL30543989 | 0.85 | DHX9 (0.70) | DHX9EGFRFGFR1KDRKEAP1 | |
| SCHEMBL30543942 | 0.85 | DHX9 (0.66) | DHX9EGFRFGFR1KDRKEAP1 | |
| SCHEMBL25433112 | 0.85 | DHX9 (0.66) | DHX9EGFRFGFR1KDRKEAP1 | |
| SCHEMBL30978299 | 0.85 | EGFR (0.52) | DHX9EGFRFGFR1KDRKEAP1 | |
| SCHEMBL21929149 | 0.83 | ALDH1A1 (0.60) | EGFRFGFR1KDRKEAP1NFE2L2 | |
| SCHEMBL26043051 | 0.83 | EGFR (0.51) | DHX9EGFRFGFR1KDRKEAP1 | |
| SCHEMBL25434054 | 0.81 | DHX9 (0.67) | DHX9EGFRFGFR1KDRHPGD | |
| SCHEMBL21929153 | 0.81 | EGFR (0.54) | DHX9EGFRFGFR1KDRKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4479380-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | Accent Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| WO-2023158795-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4479380-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | Accent Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023158795-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023158795-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX9, DHX29, DDX39B | DHX9 1/4885EGFR 4871/4885FGFR1 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.